\
&
Contact us
This was 11 months ago
LocationBudapest, Hungary
ProgrammesThe 18th SET Plan Conference is a high-level conference organised under the patronage of the Hungarian Presidency of the Council of the EU in cooperation with the Commission.
The event will provide a platform for policymakers, researchers and industry stakeholders in energy sector to establish connections and expand collaborations aimed at developing and demonstrating innovative cleantech energy solutions, while accelerating their deployment.
This year's theme, Scaling up research, innovation and competitiveness in clean energy technologies, highlights the need to reinforce the research and innovation landscape, to enhance competitiveness and sovereignty of clean energy technology value chains within the EU.
The agenda includes several thematic parallel sessions and high-level panels in the following areas: the commercialisation of innovative technologies, industrial decarbonisations, geothermal energy, energy storage, hydrogen and skills. We are expecting high-level speakers from the Commission and the Hungarian Ministry of Energy to open the conference.
More information and agenda can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.